Martin Paucar

Dr. Martin Paucar

Department of Clinical Neuroscience (CNS), Karolinska Universitetssjukhuset, Stockholm, Sweden
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AKAnnika Keller
Annika Keller
AWAna Westenberger
Ana Westenberger
MSMaria J Sobrido
Maria J Sobrido
MGMaria García-Murias
Maria García-Murias
ADAloysius Domingo
Aloysius Domingo
JOJoao R M Oliveira
Joao R M Oliveira

4 May 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ALAndrea Legati
Andrea Legati
DGDonatella Giovannini
Donatella Giovannini
GNGaël Nicolas
Gaël Nicolas
ULUriel López-Sánchez
Uriel López-Sánchez
BQBeatriz Quintáns
Beatriz Quintáns
GCGiovanni Coppola
Giovanni Coppola
Jean-Luc Battini, Giovanni Coppola and colleagues identify XPR1 mutations in several families with primary brain calcification. They further show that these mutations alter phosphate export activity, implicating defective phosphate homeostasis in the etiology of this disease. Primary familial brain calcification (PFBC) is a neurological disease characterized by calcium phosphate deposits in the basal ganglia and other brain regions and has thus far been associated with SLC20A2, PDGFB or PDGFRB mutations. We identified in multiple families with PFBC mutations in XPR1, a gene encoding a retroviral receptor with phosphate export function. These mutations alter phosphate export, implicating XPR1 and phosphate homeostasis in PFBC.

20 January 2013 in neurogenetics
Verified
Journal Article
Open access
PDF file
SHSandy Chan Hsu
Sandy Chan Hsu
RSRenee L. Sears
Renee L. Sears
RLRoberta R. Lemos
Roberta R. Lemos
BQBeatriz Quintáns
Beatriz Quintáns
AHAlden Huang
Alden Huang
GCGiovanni Coppola
Giovanni Coppola
Familial idiopathic basal ganglia calcification (IBGC) or Fahr's disease is a rare neurodegenerative disorder characterized by calcium deposits in the basal ganglia and other brain regions, which is associated with neuropsychiatric and motor symptoms. Familial IBGC is genetically heterogeneous and typically transmitted in an autosomal dominant fashion. We performed a mutational analysis of SLC20A2, the first gene found to cause IBGC, to assess its genetic contribution to familial IBGC. We recruited 218 subjects from 29 IBGC-affected families of varied ancestry and collected medical history, neurological exam, and head CT scans to characterize each patient's disease status. We screened our patient cohort for mutations in SLC20A2. Twelve novel (nonsense, deletions, missense, and splice site) potentially pathogenic variants, one synonymous variant, and one previously reported mutation were identified in 13 families. Variants predicted to be deleterious cosegregated with disease in five families. Three families showed nonsegregation with clinical disease of such variants, but retrospective review of clinical and neuroimaging data strongly suggested previous misclassification. Overall, mutations in SLC20A2 account for as many as 41 % of our familial IBGC cases. Our screen in a large series expands the catalog of SLC20A2 mutations identified to date and demonstrates that mutations in SLC20A2 are a major cause of familial IBGC. Non-perfect segregation patterns of predicted deleterious variants highlight the challenges of phenotypic assessment in this condition with highly variable clinical presentation.

1 January 2002 in Journal of NeuroVirology
Verified
Journal Article
Closed access
PDF file
FAFredrik Aronsson
Fredrik Aronsson
CLCharlotta Lannebo
Charlotta Lannebo
Martin PaucarMartin Paucar
Martin Paucar
JBJohan Brask
Johan Brask
KKKrister Kristensson
Krister Kristensson
HKHåkan Karlsson
Håkan Karlsson
Epidemiological studies have indicated an association between influenza A virus infections during fetal life and neuropsychiatric diseases. To study the po

1 February 2014 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
ASAhmed Saeed
Ahmed Saeed
FFFederico Floris
Federico Floris
UAUlla Andersson
Ulla Andersson
IPIrina A. Pikuleva.
Irina A. Pikuleva.
ALAnita Lövgren-Sandblom
Anita Lövgren-Sandblom
IBIngemar Björkhem
Ingemar Björkhem
Ahmed Saeed, Federico Floris, Ulla Andersson, Irina Pikuleva, Anita Lövgren-Sandblom, Maria Bjerke, Martin Paucar, Anders Wallin, Per Svenningsson, Ingemar Björkhem

1 February 2016 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
Martin PaucarMartin Paucar
Martin Paucar
HMHelena Malmgren
Helena Malmgren
MTMalcolm Taylor
Malcolm Taylor
JRJohn J. Reynolds
John J. Reynolds
PSPer Svenningsson
Per Svenningsson
ANAnn Nordgren
Ann Nordgren
Ataxia with oculomotor apraxia type 4 (AOA4) is an autosomal recessive (AR) disorder recently delineated in a Portuguese cohort and caused by mutations in the PNKP (polynucleotide kinase 3'-phosphatase) gene.(1) AOA4 is a progressive, complex movement disorder that includes hyperkinetic features, eye movement abnormalities, polyneuropathy, varying degrees of cognitive impairment, and obesity. PNKP mutations were initially discovered to be the cause of the severe nonprogressive syndrome microcephaly, early-onset intractable seizures, and developmental delay (MCSZ).(2) Here we describe a patient with compound heterozygous PNKP mutations presenting with an AOA4 phenotype. New features that we report include both mutations, presence of chorea, absence of oculomotor apraxia (OMA), and slow disease progression.